Clinical trials: Dementia, Lewy Body
Parkinson Disease (PD), Lewy Body Dementia (LBD)
18F-mFBG Cardiac Uptake With Lewy Body Dementia
This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation.
- Trial name
- IRP101-231 (NCT07176286)
- Testing
- 18F-MFBG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Dementias With Lewy Bodies
A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
The primary objective of the study is to achieve mass balance recovery of [14C]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
- Trial name
- NCT04023877
- Testing
- E2027
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Lewy Body Dementia, Non-DLB Dementia
Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical…
- Conditions
- Lewy Body Dementia, Non-DLB Dementia, Alzheimer's, Vascular Dementia
- Trial name
- NCT00209456
- Testing
- DatSCAN
- Where
- Germany
- Volunteers
- 326 people
- Sponsor
- GE Healthcare
Lewy Body Disease, Parkinson Disease
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9…
- Trial name
- NCT04764669
- Testing
- E2027
- Where
- 14 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Eisai Inc.
Dementia With Lewy Bodies
Expanded Access Program for CT1812 (Zervimesine)
This is a multi-center, open label, expanded access program (EAP) that will provide 100 mg CT1812 for up to one year to participants with mild-to-moderate DLB.
- Trial name
- NCT06961760
- Testing
- zervimesine
- Where
- 8 sites in United States
- Sponsor
- Cognition Therapeutics
Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
- Trial name
- NCT02669433
- Testing
- RVT-101 35 mg, RVT-101 70 mg
- Where
- 65 sites in United States, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Axovant Sciences Ltd.
Parkinson Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b as well as the effect of food and early signs of efficacy in patients with mild to moderate Parkinson´s disease.
- Trial name
- NCT04685265
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- MODAG GmbH
Mild Cognitive Impairment, Alzheimer Disease
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Alzheimer Dementia, Dementia, Vascular
- Trial name
- NCT03538522
- Testing
- N-831(Traneurocin) 10 mg QD, NA-831 (Traneurocin) 20 mg QD, NA-831 (Traneurocin) 40 mg QD
- Where
- 2 sites in New Zealand
- Volunteers
- 126 people
- Sponsor
- Biomed Industries, Inc.
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC